α1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy - Evidence for heterogeneity of chloroethylclonidine-resistant rat renal α1-adrenoceptor

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 348, Issue 4, 1993, Pages 385-395

  Michel, Martin C ^a   Büscher, Rainer ^a   Kerker, Jens ^a   Kraneis, Henner ^a   Erdbrügger, Wilhelm ^a   Brodde, Otto Erich ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

1 Adrenoceptor subtyes; Alfuzosin; Kidney; Naftopidil; Tamsulosin

Indexed keywords

5 METHYLURAPIDIL; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; CHLOROETHYLCLONIDINE; INOSITOL PHOSPHATE; METHOXAMINE; NAFTOPIDIL; NORADRENALIN; OXYMETAZOLINE; PHENTOLAMINE; PRAZOSIN; RADIOLIGAND; RECEPTOR SUBTYPE; SL 770499 10; TAMSULOSIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; HEART; ISOMER; KIDNEY; LIGAND BINDING; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SPLEEN;

ALKYLATING AGENTS; ANIMAL; CENTRIFUGATION, DENSITY GRADIENT; CEREBRAL CORTEX; CLONIDINE; DRUG RESISTANCE; IN VITRO; INOSITOL PHOSPHATES; KIDNEY; LIVER; MALE; MEMBRANES; PROSTATIC HYPERPLASIA; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; SUPPORT, NON-U.S. GOV'T;

EID: 0027441827     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/BF00171338     Document Type: Article

References (49)

1. 5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug
2. Radioreceptor assay for the determination of α1-adrenoceptor-binding material in rat plasma following a single oral administration of naftopidil
3. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
4. Subtypes of α1- and α2-adrenergic receptors
5. What is the therapeutic role of long term selective alpha-1 adrenoceptor blockade?
6. The innervation of the human prostate gland — the changes associated with benign enlargement
7. Hepatic α-adrenergic receptors
8. A randomized double-blind placebo controlled trial on the efficacy of once a day terazosin in benign prostatic hyperplasia
9. Regional distribution of α1-adrenoceptor subtypes in rat kidney
10. Heterogeneity of α1-adrenergic receptors revealed by chlorethylclonidine
11. Interaction of subtype-selective antagonists with al-adrenergic receptor binding sites in rat tissues
12. Subclassification of α1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists
13. α1-Adrenoceptors: the ability of various agonists and antagonists to discriminate between two distinct [3H]prazosin binding sites
14. In vitro characterization of the α-adrenoceptors in human prostate
15. 5-Methyl urapidil may discriminate between α1-adrenoceptors with a high affinity for WB4101 in rat lung
16. Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate
17. Alfuzosin for treatment of benign prostatic hypertrophy
18. Use of an α 1-blocker, YM 617, in the treatment of benign prostatic hypertrophy
19. α-Blocker therapy of hypertension. An unfulfilled promise
20. Binding and functional properties of alpha, adrenoceptors and of area density of smooth muscle in the canine prostate
21. Molecular biology of α-adrenergic receptors: implications for receptor classification and for structure-function relationships
22. Molecular cloning and expression of the cDNA for the α1A-adrenergic receptor. The gene for which is located on human chromosome 5
23. α1-Adrenoceptor subtypes in bovine prostate
24. Alternative mRNAs encoding the α1B-adrenergic receptor are expressed in a tissuue-dependent manner in the Sprague-Dawley rat
25. α1B-but not α1A-adrenoceptors mediate inositol phosphate generation
26. On the role of renal α-adrenergic receptors in spontaneously hypertensive rats
27. α1A and α1B-adrenoceptors enhance inositol phosphate generation in rat renal cortex
28. Comparison of selective alpha-1 blockade for alpha-receptors in human hypertrophied prostatic adenomas
29. Pharmacological subclassification of α1-adrenoceptors in vascular smooth muscle
30. Metabolic fate of the novel antihypertensive drug naftopidil
31. Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex
32. Solution-phase library screening for the identification of rare clones: isolation of an α1D-adrenergic receptor cDNA
33. Atypical alpha-1 adrenergic receptors on the rat parotid gland acinar cell
34. The α1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity
35. Pharmacological characterization of cloned α1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype
36. A difference in mode of antagonism between optical isomers of a potent selective alpha, -adrenoceptor blocker (YM-12617) and norepinephrine in isolated rabbit iris dilator and aorta
37. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin
38. Glycogen phosphorylase activation by two different α1-adrenergic receptor subtypes: methoxamine selectively stimulates a putative α1-adrenergic receptor subtype (α1a) that couples with Ca2+ influx
39. α1-Adrenoceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery
40. Different pathways of [3H]inositol phosphate formation mediated by α1A- and α1B-adrenergic receptors
41. Pertussis toxin inhibits norepinephrine-stimulated inositol phosphate formation in primary brain cell cultures
42. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy
43. Binding characteristics of naftopidil and α1-adrenoceptor antagonists to prostatic α-adrenoceptors in benign prostatic hypertrophy
44. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, paraprost-controlled study
45. Clinical evaluation of naftopidil (KT-61 1) on urinary obstruction caused by benign prostatic hypertrophy. Double-blind comparative study compared with prazosin hydrochloride
46. Effect of KT-611 (naftopidil) on the contraction of human prostatic tissue and its use in benign prostatic obstruction
47. Characterization of [3H]YM617,R-(−)-5-[2-[[2[ethoxyring(n)-3H]-(o-ethoxyphenoxy)ethyl]amino]-propryl-2-methoxybenzenesulfonamide HCI, a potent and selective alpha-1 adrenoceptor radioligand
48. Clinical efficacy and safety of long-term administration of YM617 for urinary obstruction of the lower urinary tract